FOCUS: A Dual-Mismatch crRNA Strategy Unlocks High-Fidelity One-Step SNV Detection with Cas12a
ACS Sensors · 2026
DOI: 10.1021/acssensors.6c01689 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Sensors, 2026. Verfasst von Miaojin Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Lab of Rare Pediatric Diseases, College of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang, Hunan421001,…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Polymorphism, Single Nucleotide, CRISPR-Associated Proteins, Endodeoxyribonucleases. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, Scientific Research Foundation of Hunan Provincial Education Department, Science and Technology Program of Hunan Province.
Abstract (Originalsprache)
CRISPR/Cas12a has emerged as a powerful tool for nucleic acid detection; however, its clinical utility is severely hampered by intrinsic limitations in single-nucleotide variant (SNV) discrimination, reliance on pre-processed single-stranded DNA (ssDNA) templates, and cumbersome multi-step workflows. Here, we report a novel molecular design principle by engineering crRNAs with site-specific dual mismatches (positions 12 and 14 relative to the PAM), which we systematically demonstrate to drastically enhance the SNV discrimination capability of Cas12a. Leveraging this breakthrough, we developed FOCUS (Fast One-step CRISPR-based Universalizable SNV detection system), an all-in-one CRISPR sensing platform that enables isothermal detection of SNVs from double-stranded DNA (dsDNA) by integrating amplification and detection in a single reaction system. FOCUS achieved attomolar-level sensitivity (13.15 aM) and ultrafast readout (< 20 min) for distinguishing the highly homologous survival motor neuron 1 (SMN1) and SMN2 genes—the gold standard challenge for SNV genotyping in spinal muscular atrophy (SMA) diagnostics. To validate its clinical translatability, FOCUS was successfully adapted to a low-cost, equipment-free assay using lateral flow strips and UV visualization, facilitating point-of-care testing (POCT). In a comprehensive validation across 175 clinical samples, FOCUS exhibited 100% diagnostic concordance with gold-standard methods for SMA (21 samples), high-risk HPV 16/18 (27 samples), Staphylococcus aureus (20 samples), and SARS-CoV-2 (107 samples). Collectively, our study establishes a generalizable engineering strategy for Cas12a crRNAs and presents FOCUS as a robust, versatile, and field-deployable solution for precision SNV genotyping, underscoring the translational medicine value of FOCUS in molecular diagnostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE Key Lab of Rare Pediatric Diseases, College of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang, Hunan421001, China.
- National Health Commission Key Laboratory of Neurodegenerative Diseases, University of South China, Hengyang, Hunan421001, China.
- Vascular Disease Center, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai200092, China.
- Department of Neurology, The Seventh Affiliated Hospital, Hengyang Medical School, University of South China (Hunan Provincial Veterans Administration Hospital), Changsha, Hunan410000, China.
- Department of Clinical Laboratory, Hunan University of Medicine General Hospital, Huaihua, Hunan418000, China.
- Center for Medical Genetics and Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan410078, China.
ORCID-Profile: Kun Du, Zhiqing Hu
Förderung
- Natural Science Foundation of Hunan Province
- Scientific Research Foundation of Hunan Provincial Education Department
- Science and Technology Program of Hunan Province
- National Natural Science Foundation of China
- Hengyang City Science and Technology Planning Project
Zitieren
APA
Zhou, M., Du, K., Jiang, M., Xu, X., Su, X., Xie, Y., Zhang, D., Sun, X., Peng, G., Xia, K., & Hu, Z. (2026). FOCUS: A Dual-Mismatch crRNA Strategy Unlocks High-Fidelity One-Step SNV Detection with Cas12a. ACS Sensors. https://doi.org/10.1021/acssensors.6c01689
Vancouver
Zhou M, Du K, Jiang M, Xu X, Su X, Xie Y, et al. FOCUS: A Dual-Mismatch crRNA Strategy Unlocks High-Fidelity One-Step SNV Detection with Cas12a. ACS Sensors. 2026. doi:10.1021/acssensors.6c01689
BibTeX
@article{Zhou2026,
author = {Zhou, Miaojin and Du, Kun and Jiang, Mingjun and Xu, Xin and Su, Xinran and Xie, Yixi and Zhang, Dongli and Sun, Xiaoyun and Peng, Guangnan and Xia, Kun and Hu, Zhiqing},
title = {FOCUS: A Dual-Mismatch crRNA Strategy Unlocks High-Fidelity One-Step SNV Detection with Cas12a},
journal = {ACS Sensors},
year = {2026},
doi = {10.1021/acssensors.6c01689}
}
EUVIMED